lncRNA CASC2 downregulation participates in rheumatoid arthritis, and CASC2 overexpression promotes the apoptosis of fibroblast‑like synoviocytes by downregulating IL‑17

Liu,Cheng; Guo,Xiaojun; Bai,Sunpeng; Zeng,Guangjun; Wang,Hao

doi:10.3892/mmr.2020.11018

lncRNA CASC2 downregulation participates in rheumatoid arthritis, and CASC2 overexpression promotes the apoptosis of fibroblast‑like synoviocytes by downregulating IL‑17

Authors:
- Cheng Liu
- Xiaojun Guo
- Sunpeng Bai
- Guangjun Zeng
- Hao Wang
View Affiliations

Affiliations: Department of Orthopedics, First People's Hospital of Tianmen City, Tianmen, Hubei 431700, P.R. China
Published online on: March 10, 2020 https://doi.org/10.3892/mmr.2020.11018
Pages: 2131-2137
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

lncRNA cancer susceptibility candidate 2 (CASC2) is a recently identified oncogenic lncRNA in different types of cancers. Our preliminary microarray data showed that lncRNA CASC2 was downregulated in the plasma of patients with rheumatoid arthritis (RA), indicating the involvement of this lncRNA in RA. In the present study, lncRNA CASC2 and IL‑17 in plasma were detected by reverse transcription‑quantitative PCR and ELISA, respectively. Diagnostic analyses were performed using receiver operating characteristic curves. Flow cytometry was performed to evaluate cell apoptosis. The effects of lncRNA CASC2 on IL‑17 expression were determined via western blotting. lncRNA CASC2 was found to be downregulated, while IL‑17 was upregulated in the plasma of RA patients when compared with these levels in the plasma of healthy controls. Plasma levels of lncRNA CASC2 and IL‑17 were significantly and inversely correlated in both RA patients and healthy controls. Altered plasma levels of lncRNA CASC2 and IL‑17 were able to differentiate RA patients from healthy controls. Overexpression of lncRNA CASC2 promoted, while treatment with IL‑17 inhibited the apoptosis of human fibroblast‑like synoviocytes (HFLSs) isolated from RA patients. Overexpression of lncRNA CASC2 inhibited IL‑17 expression in HFLS, while treatment with IL‑17 did not significantly affect the expression of lncRNA CASC2. Therefore, downregulation of lncRNA CASC2 is involved in RA and lncRNA CASC2 overexpression may promote the apoptosis of HFLS by downregulating IL‑17.

View Figures

View References

1	McInnes IB and Schett G: The pathogenesis of rheumatoid arthritis. N Engl J Med. 365:2205–2219. 2011. View Article : Google Scholar : PubMed/NCBI
2	McInnes IB and Schett G: Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 389:2328–2337. 2017. View Article : Google Scholar : PubMed/NCBI
3	Monti S, Montecucco C, Bugatti S and Caporali R: Rheumatoid arthritis treatment: The earlier the better to prevent joint damage. RMD Open. 1 (Suppl 1):e0000572015. View Article : Google Scholar : PubMed/NCBI
4	Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D, et al: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease--modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: Systematic review and economic evaluation. Health Technol Assess. 20:1–610. 2016. View Article : Google Scholar
5	Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, et al: Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 75:3–15. 2016. View Article : Google Scholar : PubMed/NCBI
6	Choy EH and Panayi GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 344:907–916. 2001. View Article : Google Scholar : PubMed/NCBI
7	Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, et al: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. celecoxib long-term arthritis safety study. JAMA. 284:1247–1255. 2000. View Article : Google Scholar : PubMed/NCBI
8	Pickens SR, Volin MV, Mandelin AM II, Kolls JK, Pope RM and Shahrara S: IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol. 184:3233–3241. 2010. View Article : Google Scholar : PubMed/NCBI
9	Song J, Kim D, Han J, Kim Y, Lee M and Jin EJ: PBMC and exosome-derived Hotair is a critical regulator and potent marker for rheumatoid arthritis. Clin Exp Med. 15:121–126. 2015. View Article : Google Scholar : PubMed/NCBI
10	Yang KY and Chen DL: Shikonin inhibits inflammatory response in rheumatoid arthritis synovial fibroblasts via lncRNA-NR024118. Evid Based Complement Alternat Med. 2015:6317372015. View Article : Google Scholar : PubMed/NCBI
11	Pei Z, Du X, Song Y, Fan L, Li F, Gao Y, Wu R, Chen Y, Li W, Zhou H, et al: Down-regulation of lncRNA CASC2 promotes cell proliferation and metastasis of bladder cancer by activation of the Wnt/β-catenin signaling pathway. Oncotarget. 8:18145–18153. 2017. View Article : Google Scholar : PubMed/NCBI
12	Cao Y, Xu R, Xu X, Zhou Y, Cui L and He X: Downregulation of lncRNA CASC2 by microRNA-21 increases the proliferation and migration of renal cell carcinoma cells. Mol Med Rep. 14:1019–1025. 2016. View Article : Google Scholar : PubMed/NCBI
13	Lee SY, Kwok SK, Son HJ, Ryu JG, Kim EK, Oh HJ, Cho ML, Ju JH, Park SH and Kim HY: IL-17-mediated Bcl-2 expression regulates survival of fibroblast-like synoviocytes in rheumatoid arthritis through STAT3 activation. Arthritis Res Ther. 15:R312013. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Zhang Y, Xu YZ, Sun N, Liu JH, Chen FF, Guan XL, Li A, Wang F, Zhao QF, Wang HY, et al: Long noncoding RNA expression profile in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Res Ther. 18:2272016. View Article : Google Scholar : PubMed/NCBI
16	Huang XD, Dai JG, Lin KT, Liu M, Ruan HT, Zhang H, Liu WG, He MX and Zhao M: Regulation of IL-17 by lncRNA of IRF-2 in the pearl oyster. Fish Shellfish Immunol. 81:108–112. 2018. View Article : Google Scholar : PubMed/NCBI
17	Huang W, Thomas B, Flynn RA, Gavzy SJ, Wu L, Kim SV, Hall JA, Miraldi ER, Ng CP, Rigo F, et al: DDX5 and its associated lncRNA Rmrp modulate TH17 cell effector functions. Nature. 528:517–522. 2015. View Article : Google Scholar : PubMed/NCBI
18	Bartok B and Firestein GS: Fibroblast-like synoviocytes: Key effector cells in rheumatoid arthritis. Immunol Rev. 233:233–255. 2010. View Article : Google Scholar : PubMed/NCBI
19	Zou S, Wang C, Cui Z, Guo P, Meng Q, Shi X, Gao Y, Yang G and Han Z: β-Elemene induces apoptosis of human rheumatoid arthritis fibroblast-like synoviocytes via reactive oxygen species-dependent activation of p38 mitogen-activated protein kinase. Pharmacol Rep. 68:7–11. 2016. View Article : Google Scholar : PubMed/NCBI
20	Li S, Jin Z and Lu X: MicroRNA-192 suppresses cell proliferation and induces apoptosis in human rheumatoid arthritis fibroblast-like synoviocytes by downregulating caveolin 1. Mol Cell Biochem. 432:123–130. 2017. View Article : Google Scholar : PubMed/NCBI